Intraarterial gelation of injectable cationic pH/temperature-sensitive radiopaque embolic hydrogels in a rabbit hepatic tumor model and their potential application for liver cancer treatment

RSC Advances ◽  
2016 ◽  
Vol 6 (53) ◽  
pp. 47687-47697 ◽  
Author(s):  
Cong Truc Huynh ◽  
Quang Vinh Nguyen ◽  
Jae Seung Lym ◽  
Bong Sup Kim ◽  
Dai Phu Huynh ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Cancer Treatment ◽  
Potential Application ◽  
Tumor Model ◽  
Hepatic Tumor ◽  
Local Temperature ◽  
Temperature Sensitive ◽  
Amino Ester

Radiopaque embolic solutions employing cationic poly(amino ester urethane)-based copolymers are injected into a rabbit hepatic tumor artery and form hydrogels in response to local temperature and pH for chemoembolization.

scholarly journals Poly(beta-amino ester) Nanoparticles Enable Tumor-Specific TRAIL Secretion and a Bystander Effect to Treat Liver Cancer

2021 ◽  
Author(s):  
Hannah J. Vaughan ◽  
Camila G. Zamboni ◽  
Nicholas P. Radant ◽  
Pranshu Bhardwaj ◽  
Esther Revai Lechtich ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Bystander Effect ◽  
Amino Ester

scholarly journals Nanoparticles in enhancing microwave imaging and microwave Hyperthermia effect for liver cancer treatment

2021 ◽  
Vol 60 (1) ◽  
pp. 223-236
Author(s):  
Walaa Maamoun ◽  
Mohamed I. Badawi ◽  
Ayman A Aly ◽  
Y. Khedr
Keyword(s):  
Silver Nanoparticles ◽  
Liver Cancer ◽  
Cancer Treatment ◽  
Electromagnetic Waves ◽  
Microwave Imaging ◽  
Healthy Tissue ◽  
Cancer Tissue ◽  
Hyperthermia Treatment ◽  
Hyperthermia Therapy ◽  
Surrounding Healthy Tissue

Abstract Hyperthermia therapy is a promising therapy for liver cancer treatment that utilizes external electromagnetic waves to heat the tumor zone to preferentially kill or minimize cancer cells. Nevertheless, it’s a challenge to realize localized heating of the cancer tissue without harming the surrounding healthy tissue. This research proposes to utilize nanoparticles as microwave absorbers to enhance microwave imaging and achieve localized hyperthermia therapy. A realistic 3D abdomen model has been segmented using 3D Slicer segmentation software, and then the obtained segmented CAD model exported to Computer Simulation Technology (CST STUDIO) for applying the Finite Element Modeling (FEM). Next investigating both imaging and treatment capability. Finally, the specific absorption rate (SAR) and temperature distribution were computed without nanoparticles and with different types of nanoparticles such as gold (GNPs) and silver nanoparticles at frequency 915 MHz. By comparing the achived results, it was seen that Silver nanoparticles can make a great enhancement in raising the temperature. However, this result was unsatisfactory but, after adding gold nanoparticles the temperature exceed 42°C, at frequency 915 MHz which is achieving the hyperthermia treatment without harming the nearby healthy tissue, GNPs also can achieve a great enhancement in SAR result

scholarly journals Metformin induces Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer

2021 ◽  
Vol 40 (1) ◽  
Author(s):  
Jingjing Yang ◽  
Yulu Zhou ◽  
Shuduo Xie ◽  
Ji Wang ◽  
Zhaoqing Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Morphological Changes ◽  
Tumor Model ◽  
Independent Manner ◽  
Regulated Cell Death ◽  
Anti Cancer ◽  
Cancer Agent ◽  
Approved Drugs

Abstract Background Ferroptosis is a newly defined form of regulated cell death characterized by the iron-dependent accumulation of lipid peroxidation and is involved in various pathophysiological conditions, including cancer. Targeting ferroptosis is considered to be a novel anti-cancer strategy. The identification of FDA-approved drugs as ferroptosis inducers is proposed to be a new promising approach for cancer treatment. Despite a growing body of evidence indicating the potential efficacy of the anti-diabetic metformin as an anti-cancer agent, the exact mechanism underlying this efficacy has not yet been fully elucidated. Methods The UFMylation of SLC7A11 is detected by immunoprecipitation and the expression of UFM1 and SLC7A11 in tumor tissues was detected by immunohistochemical staining. The level of ferroptosis is determined by the level of free iron, total/lipid Ros and GSH in the cells and the morphological changes of mitochondria are observed by transmission electron microscope. The mechanism in vivo was verified by in situ implantation tumor model in nude mice. Results Metformin induces ferroptosis in an AMPK-independent manner to suppress tumor growth. Mechanistically, we demonstrate that metformin increases the intracellular Fe2+ and lipid ROS levels. Specifically, metformin reduces the protein stability of SLC7A11, which is a critical ferroptosis regulator, by inhibiting its UFMylation process. Furthermore, metformin combined with sulfasalazine, the system xc− inhibitor, can work in a synergistic manner to induce ferroptosis and inhibit the proliferation of breast cancer cells. Conclusions This study is the first to demonstrate that the ability of metformin to induce ferroptosis may be a novel mechanism underlying its anti-cancer effect. In addition, we identified SLC7A11 as a new UFMylation substrate and found that targeting the UFM1/SLC7A11 pathway could be a promising cancer treatment strategy.

Correlation between Hepatic Tumor Blood Flow and Glucose Utilization in a Rabbit Liver Tumor Model

Radiology ◽  
2006 ◽  
Vol 239 (3) ◽  
pp. 740-750 ◽  
Author(s):  
Errol E. Stewart ◽  
Xaiogang Chen ◽  
Jennifer Hadway ◽  
Ting-Yim Lee
Keyword(s):  
Blood Flow ◽  
Liver Tumor ◽  
Glucose Utilization ◽  
Tumor Model ◽  
Hepatic Tumor ◽  
Rabbit Liver ◽  
Tumor Blood Flow

Metal-organic framework IRMOFs coated with a temperature-sensitive gel delivering norcantharidin to treat liver cancer

2021 ◽  
Vol 27 (26) ◽  
pp. 4203-4215
Author(s):  
Xiu-Yan Li ◽  
Qing-Xia Guan ◽  
Yu-Zhou Shang ◽  
Yan-Hong Wang ◽  
Shao-Wa Lv ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Metal Organic Framework ◽  
Temperature Sensitive ◽  
Metal Organic ◽  
Organic Framework

Treatment of solid tumors using bispecific anti-PDL-1/ICOS antibody

2021 ◽  
Author(s):  
Martin Perez-Santos ◽  
Maricruz Anaya-Ruiz ◽  
Gabriela Sanchez-Esgua ◽  
Luis Villafaña-Diaz ◽  
Diana Barron-Villaverde
Keyword(s):  
Clinical Trials ◽  
T Cells ◽  
Tumor Microenvironment ◽  
Cancer Treatment ◽  
Potential Application ◽  
Poor Prognosis ◽  
Bispecific Antibody ◽  
Control Points ◽  
Immune Control ◽  
Ct26 Model

PD-L1 and ICOS are immune control points in cancer and their presence in cancer tends to have a poor prognosis. WO2019122882 patent describes a bispecific antibody that targets PDL-1/ICOS with the potential application of cancer treatment. WO2019122882 patent describes a bispecific antibody with antitumor efficacy in CT26 model through of the depletion of TReg cells and improved ratio of CD8+ T cells: TReg in tumor microenvironment. The anti-PDL-1/ICOS antibody is new; however, only preclinical assays are shown using colon carcinoma model. So far, there are no reports of clinical trials to evaluate the safety, toxicity and efficacy, but it will be of great interest to analyze in the future if this antibody surpasses the action of the combinatorial therapy in cancer.

Sign in / Sign up

Export Citation Format

Share Document